Spot on. The other approach they could take, alongside 150mg dose, is the use of tech that increases absorption of CBD. If you can't up the dose, try upping the amount of drug candidate that actually gets metabolised.
Incannex recently acquired a formulation during their APIRx acquisition, that greatly optimised the absorption of CBD for a chewing gum product, and I believe there are other similar patented processes out there. Maybe CANN could license one of them.
It truly does boggle the mind that they wasted all this time and money on phase 3 trials with the highest dose as 100mg, with no absorption optimisation. I'm not quite sure what they were thinking. I don't hold CANN, but I'm still very disappointed by this result. At the tend of the day, what matters the most is getting useful products to the public, and CANN could have been on track to do that.
CAN Price at posting:
20.0¢ Sentiment: Sell Disclosure: Not Held
(20min delay)